Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Haemonetics Gets US FDA Approval for PerQseal Elite Vascular Closure System

Haemonetics Gets US FDA Approval for PerQseal Elite Vascular Closure System

MT newswireMT newswire2026/10/19 21:00
05:00 PM EDT, 10/19/2026 (MT Newswires) -- Haemonetics (HAE) has received approval from the US Food and Drug Administration for its PerQseal Elite vascular closure system for large-bore arterial procedures used in structural heart and endovascular interventions, the company said late Monday. The ELITE clinical study showed no major device-related vascular access site complications through 30 days and a mean time to hemostasis of less than one minute, the company said. Haemonetics plans to present clinical data on the system at the Transcatheter Cardiovascular Therapeutics conference in late October.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

JPMorgan Chief Global Strategist: Tech stock trading has entered a phase of volatility and uncertainty; investors should diversify their AI holdings

David Kelly, Chief Global Strategist at JPMorgan Asset Management, stated that as the artificial intelligence (AI) industry shows signs of entering a new phase characterized by increased volatility and rising technological uncertainty, investors should diversify their AI-related holdings.

智通财经•2026/11/17 04:11
JPMorgan Chief Global Strategist: Tech stock trading has entered a phase of volatility and uncertainty; investors should diversify their AI holdings

Cramer Most Bearish on Stock Plummeting 61%: Intel (INTC.US) Lowers Guidance Amid Executive Stock Purchases

Jim Cramer called Intel his top stock pick, but its share price is down about 61% from its historical high. Intel lowered its Q4 revenue guidance to below $16.5 billion. CEO Pat Gelsinger recently bought 150,000 additional shares. Meanwhile, a shareholder lawsuit accuses the company of underestimating the weakness in the PC market.

智通财经•2026/11/17 03:51
Cramer Most Bearish on Stock Plummeting 61%: Intel (INTC.US) Lowers Guidance Amid Executive Stock Purchases